IMTX Immatics NV

In a report released on November 17, Jonathan Chang from SVB Securities reiterated a Buy rating on Immatics (IMTX - Research Report), with a price target of $17.00. The company's shares closed last Friday at $10.55.Chang covers the Healthcare sector, focusing on stocks such as Bicycle Therapeutics, Immatics, and ImmunoGen. According to TipRanks, Chang has an average return of -13.0% and a 28.57% success rate on recommended stocks. Immatics has an analyst consensus of Moderate Buy, with a price target consensus of $22.50, implying an 113.27% upside from current levels. In a report released on November 17, Chardan Capital also reiterated a Buy rating on the stock with a $28.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-their-buy-rating-for-immatics-imtx?utm_source=advfn.com&utm_medium=referral